Radiolabeled TSPO Targeted Molecular Probe in Alzheimer's Disease.
NCT ID: NCT07105956
Last Updated: 2025-08-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
8 participants
OBSERVATIONAL
2025-09-01
2026-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Establish Diagnostic and Prognostic Models for Preclinical AD Patients Based on Multimodal MRI, Behavioral, Genetic, and Plasma Biomarkers
NCT06561906
Development of Multimodal Fusion Warning System and Non-invasive Techniques for Early Alzheimer's Detection.
NCT05978830
Multi-modality MRI Study on Differences in Conversion of aMCI Patients With APOEε4 to AD
NCT02225964
MRI of Alzheimer's Disease Imaging Amyloid Plaques in Persons With and Without Memory Problems
NCT00413621
[18F]NIDF PET Imaging in Tau-related Diseases
NCT07306598
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Volunteers are not limited by gender, and the age range is from 18 to 75 years old, including both ends.
* The patient is diagnosed with Alzheimer's disease (AD), supported by a positive amyloid PET scan.
* The patient has completed Tau PET scan.
Exclusion Criteria
* Use of anti-inflammatory drugs, including corticosteroids and immunosuppressants, within the past 14 days, which may interfere with the accuracy of inflammation imaging.
* Presence of other coexisting neurological diseases, such as stroke, Parkinson's disease, brain tumors, or mental disorders, including depressive disorder and schizophrenia.
* Severe cardiac, pulmonary, hepatic, or renal dysfunction, or uncontrolled systemic diseases; 5. Presence of metal implants contraindicated for MRI, including but not limited to cardiac pacemakers, artificial heart valves, and metal stents.
* Claustrophobia or inability to tolerate prolonged examinations.
* Pregnant women (defined as those with a positive urine pregnancy test) or breastfeeding women.
* Patients whose physical condition is unsuitable for radioactive tracer-based imaging examinations.
* Other circumstances deemed unsuitable for participation in the trial by the researcher.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nanjing First Hospital, Nanjing Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Feng Wang
Chief physician
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nanjing First Hospital
Nanjing, Jingasu, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KY20250624-06-KS-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.